Dario Dornbierer is a Pharmaceutical Scientist (MSc, ETH Zurich), Pharmacist, Neuroscientist (Dr. sc. ETH), and a start-up entrepreneur. During his MSc and PhD at the Psychiatric University Hospital Zurich, he investigated the sleep pharmacological effects of GHB and its repurposing potential for treating mood disorders. As a postdoctoral researcher, he secured two innovation grants (UZH Entrepreneur Fellowship and SNF Bridge PoC) to develop synthetic analogues of the Amazonian plant hallucinogen Ayahuasca for psychiatric treatment. Concurrently, he initiated a Innosuisse-funded project at the Human Sleep Pharmacology Lab in Zurich to explore the repurposing of the anesthetic compound dexmedetomidine for promoting deep sleep in hyperarousal-related insomnia. Building on this work, Dario co-founded Reconnect Labs, a University of Zurich spin-off dedicated to developing innovative, regenerative drug therapies for mental health. He also co-founded Galventa, a start-up focused on creating novel nutraceuticals for sleep health. Passionate about the intricate relationship between the brain and mind, Dario is driven by a vision of how promoting sleep and psychedelic states can foster healing. Currently, he serves as the Chief Scientific Officer and Board Member of Reconnect Labs and Galventa.